AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Travere Therapeutics Inc. (TVTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

23.57

0.24 (1.03%)

At close: Feb 20, 2025, 3:59 PM

21.01

-10.86%

After-hours: Feb 20, 2025, 05:19 PM EST

undefined% (undefined)

Bid	21.01
Market Cap	2.05B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.52
PE Ratio (ttm)	-5.21
Forward PE	n/a
Analyst	Buy

Ask	24.4
Volume	1,035,348
Avg. Volume (20D)	1,429,122
Open	23.37
Previous Close	23.33
Day's Range	23.14 - 23.65
52-Week Range	5.12 - 25.29
Beta	undefined

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 8, 2012

Employees 380

Stock Exchange NASDAQ

Ticker Symbol TVTX

Website https://www.travere.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 6.07% from the latest price.

Buy 84.62%

Hold 7.69%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Travere Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

Travere Therapeutics shares are trading lower. The... Unlock content with Pro Subscription

1 week ago

+12.56%

Travere Therapeutics shares are trading higher after the company announced the completion of its Type C meeting with the FDA and plans to submit a supplemental new drug application.

News

4 days ago · zacks.com

Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for s...

1 week ago · zacks.com

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

Travere (TVTX) Moves 12.6% Higher: Will This Strength Last?

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago · zacks.com

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 42.6% in Travere (TVTX). While the effectiveness of this highly sought-after metric is questionable, the positi...

2 months ago · seekingalpha.com

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setb...